HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older and fall into at least one of the following five groups:
- Group 1: You have tested positive for hepatitis B (but not HIV), you have not yet started treatment (or stopped treatment more than 1 year ago and have taken it for no more than 7 days recently), and your doctor considers you suitable for a tenofovir-based medication
- Group 2: You have tested positive for hepatitis B (but not HIV), you recently developed symptoms of hepatitis, and your liver enzyme levels are significantly elevated (more than 10 times the normal level)
- Group 3: You have both hepatitis B and HIV, you have not yet started treatment (or stopped more than 1 year ago and have taken it for no more than 7 days recently), and your doctor considers you suitable for a tenofovir-based medication
- Group 4: You have both hepatitis B and HIV, you have been on tenofovir-based treatment for at least 4 years, and you are still testing positive for hepatitis B
- Group 5: You have a confirmed history of chronic hepatitis B (shown by two tests taken 6 months apart), but you now test negative for the hepatitis B surface antigen — whether or not you have HIV
Who may not be able to join:
- You also have hepatitis C, confirmed by both an antibody test and a virus-detection test
- You are currently pregnant or have been pregnant in the past 6 weeks
- You have severe liver disease (advanced cirrhosis) that is detectable during a physical examination
- You are unlikely to be able to stay in Lusaka for the full length of the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Vinikoor, MD, University of Alabama at Birmingham
Phone: 205-934-5191
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Intrahepatic Immune Cell Subset Frequencies; Number of Differentially Expressed Hepatic Genes Associated with HBsAg Reduction/Loss
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.